News Search Results
Jun 05, 2025, 06:00 ET Navigate Patient Solutions Adds Vance Thompson, MD, David Cox, and Matthew P. Jensen to Medical Advisory Board
to empower ophthalmology practices through a unique solution that activates, educates, and motivates patients." Navigate Patient Solutions is building something extraordinary in ophthalmology—a comprehensive, forward-thinking patient engagement solution. We invite ophthalmology practices
More news about: Navigate Patient Solutions
Jun 04, 2025, 20:23 ET Innovent's IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for Immuno-resistant Squamous Non-Small Cell Lung Cancer
that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products
More news about: Innovent Biologics
Jun 04, 2025, 20:00 ET Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma
that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13), today jointly announce
More news about: Innovent Biologics
Jun 03, 2025, 20:00 ET 2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in Advanced Non-small Cell Lung Cancer
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announced the third oral presentation of clinical data for IBI363 (first-in-class PD-1/IL-2α-bias bispecific
More news about: Innovent Biologics
Jun 03, 2025, 17:25 ET Tixel i® Demonstrates Sustained Improvements in Dry Eye Symptoms
KNOXVILLE, Tenn., June 3, 2025 /PRNewswire/ -- A new article in JOJ Ophthalmology confirms Tixel i® provides sustained, strong clinical outcomes for patients with Evaporative Dry Eye Disease (DED) caused by Meibomian
More news about: Novoxel Inc.
Jun 03, 2025, 15:23 ET Kaiser Permanente opens new expansion at Everett Medical Center
orthopedics, spine care, sports medicine, gynecology, urogynecology, otolaryngology, allergy care, nephrology, pulmonary care, mental health care, ophthalmology, optometry, and physical therapy. With the expansion, the medical center will offer six additional specialty care departments to serve Kaiser
More news about: Kaiser Permanente
Jun 03, 2025, 12:22 ET Historic $40 Million Gift to CU Anschutz Dept. of Ophthalmology will Fuel Research and New Therapies
Department of Ophthalmology received a historic $40 million gift to treat and potentially cure eye diseases like macular degeneration and glaucoma,
More news about: University of Colorado Anschutz
Jun 02, 2025, 21:00 ET ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI343 (Novel Anti-CLDN18.2 ADC) From the Phase 1 Clinical Study in Patients with Advanced Pancreatic Cancer
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, updated the Phase 1 study results of IBI343, a novel anti-CLDN18.2 ADC, for the treatment of advanced pancreatic cancer
More news about: Innovent Biologics
Jun 01, 2025, 20:00 ET 2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical Studies in Advanced Colorectal Cancer
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the clinical data of IBI363 (first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein)
More news about: Innovent Biologics
May 31, 2025, 21:39 ET ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunotherapy-treated Advanced Malignant Melanoma
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces the data from Phase 1 and Phase 2 clinical studies of IBI363, first-in-class PD-1/IL-2α-bias bispecific
More news about: Innovent Biologics
May 30, 2025, 10:39 ET Sun Pharma Completes its Acquisition of Checkpoint Therapeutics
company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines,
More news about: Sun Pharma
May 30, 2025, 10:00 ET Mabwell Receives NMPA Approval for Albipagrastim alfa for Injection (MAILISHENG)
R&D engine, including 12 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. Of these, 4 products have been approved and commercialized, 1 product
More news about: Mabwell
May 29, 2025, 20:15 ET Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
May 29, 2025, 12:01 ET NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA
unmet need. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. ST is a member of the World Orphan Drug Alliance (WODA). Additional information
More news about: Specialised Therapeutics
May 28, 2025, 17:40 ET Metropolitan Animal Specialty Hospital (MASH) Los Angeles Will Remain Open Under New Ownership Led by a Distinguished Existing Specialty and Emergency Veterinarian Team
Animal Medical Center in New York City, followed by an ophthalmology internship at Animal Eye Guys in Miami. She then completed a residency in ophthalmology at North Carolina State University. Her clinical interests
More news about: Metropolitan Animal Specialty Hospital (MASH)
May 28, 2025, 10:00 ET Astellas Announces Second Annual Patient Advocacy Organization (PAO) Action Week™ To Empower Patients and Caregivers
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
May 28, 2025, 10:00 ET American Academy of Pediatric Dentistry Names New Board Officers and Trustees at Annual Meeting
children. His son is a dentist and physician, specializing in Oral and Maxillofacial Surgery. His oldest daughter is a physician specializing in ophthalmology, and his youngest daughter is a mental health counselor focused on youth and addictions. Jacob K. LeeVICE
More news about: American Academy of Pediatric Dentistry
May 28, 2025, 08:30 ET InMode Response Letter to DOMA by Moshe Mizrahy, CEO, Dated May 28, 2025
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com. Forward-Looking
More news about: InMode Ltd.
May 28, 2025, 08:00 ET Formosa Pharmaceuticals and Adalvo Limited Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain
four days post-surgery) and low incidence of adverse events (<2%) were highlighted as key drivers to prescribing APP13007. The European ophthalmology market reached $16 billion in 2024, with Germany and the UK leading as the largest
More news about: Formosa Pharmaceuticals Inc.,
May 28, 2025, 08:00 ET SECTRA EQUIPS MULTI-SITE US HEALTH SYSTEM WITH ENTERPRISE IMAGING AS A CLOUD SERVICE AND ACCELERATES AI ADOPTION FOR IMPROVED PATIENT DIAGNOSTICS
worldwide. Sectra offers a complete enterprise solution comprised of imaging modules (radiology, cardiology, pathology, orthopedics, genomics and ophthalmology), and a robust VNA. Visit Sectra's website to read more about Sectra and why it's top-ranked in "
More news about: Sectra AB
May 26, 2025, 07:04 ET Happiest Health Launches Happiest Physio Clinic in Koramangala, Bengaluru
division brings forth unique away-from-hospital clinics specializing in multiple disciplines. We will soon be offering cardiology, dental, ENT, ophthalmology, orthopedic services and more. The Wellness business division too will have a range of clinics including Ayurveda, weight management &
More news about: Happiest Health
May 26, 2025, 06:53 ET Happiest Health Launches Happiest Physio Clinic in Koramangala, Bengaluru
division brings forth unique away-from-hospital clinics specializing in multiple disciplines. We will soon be offering cardiology, dental, ENT, ophthalmology, orthopedic services and more. The Wellness business division too will have a range of clinics including Ayurveda, weight management &
More news about: Happiest Health
May 23, 2025, 13:47 ET Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths
monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific
More news about: Celltrion
May 23, 2025, 10:00 ET Mabwell Announces Clinical Data of Multiple ADCs to be presented at 2025 ASCO Annual Meeting
R&D engine, including 12 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. Of these, 3 products have been approved and commercialized, 1 product has been filed for market approval,
More news about: Mabwell
May 21, 2025, 11:00 ET Astellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology, and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.